Major Upgrade for Citius Oncology: Lymphir Launch Anticipation
Citius upgraded to Buy ($6). Lymphir launches in Q4 at high prices ($300K). Sales should jump fast starting in 2026.
NOTRELOAD AI
Amneal's Generic Bimatoprost Ophthalmic Solution Approved by FDA
Amneal Pharmaceuticals has received FDA approval for a generic eye drop (bimatoprost 0.01%) used to treat high eye pressure linked to glaucoma and ocular hypertension.
Major Step Towards the Quantum Internet: Connecting Quantum Computers
IonQ has achieved a significant technological advancement in partnership with the Air Force Research Lab (AFRL), demonstrating the ability to efficiently connect quantum computers over long distances.
Scholar Rock’s Apitegromab Application Declined by FDA Due to Manufacturer Issues
Scholar Rock’s potential new SMA treatment, Apitegromab, received a delay from the FDA due to manufacturing site issues, not the drug's safety or effectiveness.
Wells Fargo Upgrades CoreWeave: Growth Potential Through 2026
Wells Fargo significantly raised its rating and price target for CoreWeave, moving the stock to Overweight and citing "multiple" factors that signal strong growth potential.
Firefly Aerospace Q1 Update: Losses Grow, But Steady Progress Continues
Firefly Aerospace's first post-IPO report showed wider losses and lower revenue. The CEO claims "steady progress", noting they are increasing rocket production to meet strong demand for space launches, especially for national security missions.